Advancements in Applications of Surface Modified Nanomaterials for Cancer Theranostics

Ahmad, Iffat Zareen; Kuddus, Mohammed; Tabassum, Heena; Ahmad, Ausaf; Mabood, Abdul

doi:10.2174/1389200218666171002122039

“…As discussed earlier, BC is the most widely encountered malignancy with a high mortality rate [ 83 ]. The usual 5-year endurance of women with BC is closely correlated with the tumor phase (98% of 5-year survival at stages 0–1 compared to 85%, 60%, and 20% for stages 2,3, and 4, respectively) [ 43 ].…”

Section: Nanostructures For Bc Diagnosismentioning

confidence: 99%

“…The usual 5-year endurance of women with BC is closely correlated with the tumor phase (98% of 5-year survival at stages 0–1 compared to 85%, 60%, and 20% for stages 2,3, and 4, respectively) [ 43 ]. Early detection of BC can significantly reduce the mortality rate associated with the disease, thus improving management and treatment [ 83 ]. Conventional tools for cancer diagnosis, including tissue sampling, mammography, contrast-enhanced mammography, ultrasound, MRI, positron emission tomography, and computerized tomographic examination, are still the most employed methods.…”

Section: Nanostructures For Bc Diagnosismentioning

confidence: 99%

Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements

Arshad

¹

,

Kiani

²

,

Rahdar

³

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) is a highly metastatic multifactorial disease with various histological and molecular subtypes. Due to recent advancements, the mortality rate in BC has improved over the past five decades. Detection and treatment of many cancers are now possible due to the application of nanomedicine in clinical practice. Nanomedicine products such as Doxil® and Abraxane® have already been extensively used for BC adjuvant therapy with favorable clinical outcomes. However, these products were designed initially for generic anticancer purposes and not specifically for BC treatment. With a better understanding of the molecular biology of BC, several novel and promising nanotherapeutic strategies and devices have been developed in recent years. In this context, multi-functionalized nanostructures are becoming potential carriers for enhanced chemotherapy in BC patients. To design these nanostructures, a wide range of materials, such as proteins, lipids, polymers, and hybrid materials, can be used and tailored for specific purposes against BC. Selective targeting of BC cells results in the activation of programmed cell death in BC cells and can be considered a promising strategy for managing triple-negative BC. Currently, conventional BC screening methods such as mammography, digital breast tomosynthesis (DBT), ultrasonography, and magnetic resonance imaging (MRI) are either costly or expose the user to hazardous radiation that could harm them. Therefore, there is a need for such analytical techniques for detecting BC that are highly selective and sensitive, have a very low detection limit, are durable, biocompatible, and reproducible. In detecting BC biomarkers, nanostructures are used alone or in conjunction with numerous molecules. This review intends to highlight the recent advances in nanomedicine in BC treatment and diagnosis, emphasizing the targeting of BC cells that overexpress receptors of epidermal growth factors. Researchers may gain insight from these strategies to design and develop more tailored nanomedicine for BC to achieve further improvements in cancer specificity, antitumorigenic effects, anti-metastasis effects, and drug resistance reversal effects.

show abstract

Surface Modification of Nanoparticles for Targeted Drug Delivery

Patel

¹

,

Hanini

²

,

Shah

³

et al. 2019

View full text Add to dashboard Cite

the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Surface Modification of Nanoparticles for Targeted Drug Delivery

Patel¹,

Hanini²,

Shah³

et al. 2019

Surface Modification of Nanoparticles for Targeted Drug Delivery

View full text Add to dashboard Cite

the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Advancements in Applications of Surface Modified Nanomaterials for Cancer Theranostics

Cited by 8 publications

References 0 publications

Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements

Nano-Based Theranostic Platforms for Breast Cancer: A Review of Latest Advancements

Surface Modification of Nanoparticles for Targeted Drug Delivery

Surface Modification of Nanoparticles for Targeted Drug Delivery

Contact Info

Product

Resources

About